Driving Corporate Strategy in the Boardroom
New York, NY
Ensuring that a company has a sound long-term corporate strategy is among a board's most important functions and is the ultimate measure of its stewardship. Indeed, over the past ten years, according to the 2015 NACD Blue Ribbon Commission on Strategy Development, directors have consistently selected strategic planning and oversight as the leading issue for board focus in the coming year.
In this program, we will examine the board's critical role in ensuring that the company's business strategy promotes the creation of long-term value. Among other matters, our panel will discuss and debate questions such as:
1. What is the board's proper role in strategy relative to management's role? When does strategic planning become micro-managing?
2. What are some of the "best practices" in developing a strategic plan?
3. How should a board assess the tradeoff between strategic goals and risk?
4. What is the board's role in setting targets and monitoring the success of the strategy?
5. How can directors level the informational playing field with management?
Additional panelists to be announced.
Location and Time
50 Vanderbilt Ave
New York, NY 10017
Nicholas M. DonofrioDirector, Advanced Micro Devices, Inc., Delphi Automotive plc, Bank of New York Mellon, Liberty Mutual, O’Brien & Gere, Sporxil, and MITRE IBM Fellow Emeritus & EVP Innovation and Technology (Ret.)
Nicholas Donofrio currently serves on the boards of Advanced Micro Devices Inc. and Delphi Automotive plc, and chairs the innovation and technology committee for both companies. In addition, he sits on the board of Bank of New York Mellon, where he chairs the technology committee, and is a director of Liberty Mutual, O’Brien & Gere, Sporxil, MITRE and National Association of Corporate Directors. He is a 44-year IBM veteran who held the coveted positions of Executive Vice President Innovation and Technology and was also selected as an IBM Fellow, the company's highest technical honor.
Mr. Donofrio holds seven technology patents and is a member of numerous technical and science honor societies. He has long been focused on advancing educational and career development opportunities for underrepresented minorities and women in the STEM disciplines, a commitment that has been recognized with numerous honors and awards. He is a member of the National Academy of Engineering, a Fellow of the American Academy of Arts and Sciences, a Fellow of Britain's Royal Academy of Engineering, and a Fellow of the Institute for Electrical and Electronics Engineers. Mr. Donofrio has led and participated in numerous governmental and educational special initiatives including the Council on Competitiveness and the U.S. Department of Education’s Commission on the Future of Higher Education. Recently he chaired a National Academy of Engineering initiative that resulted in the March 2015 release of a report titled Making Value for America: Embracing the Future of Manufacturing, Technology, and Work. He is the recipient of several industry, government and academic awards.
Mr. Donofrio holds a master's degree and a bachelor's degree in electrical engineering from Syracuse University and Rensselaer Polytechnic Institute, respectively. He has received honorary doctorates from Polytechnic University (now NYU-Poly), University of Warwick-UK, Marist College, University of Edinburgh-UK, Pace University, National University of Ireland-Maynooth and Syracuse University.
Adele GulfoChief Strategy Officer, Mylan and Director, Bemis, Inc.
Adele Gulfo serves as Mylan’s Chief Strategy Officer and is a director of Bemis, Inc. (BMS) serving on the company’s Audit Committee. As a member of Mylan’s Executive Leadership Team, she focuses on their key growth drivers, including the company’s expansion into new geographies and the development and growth of its global Specialty pharmaceutical franchise.
Previously, Ms. Gulfo served as president and general manager of Pfizer's U.S. Primary Care business unit, which included the Managed Markets and Commercial Operations for all of Pfizer's Biopharmaceutical business units. Immediately prior to joining Mylan, Ms. Gulfo served as regional president of Latin America in Pfizer's Emerging Markets business unit. Prior to joining Pfizer, Ms. Gulfo led AstraZeneca’s multi-billion dollar cardiovascular business. She then became vice president of Business Development, Innovation and Design for Launch at Astra-Zeneca Pharmaceuticals.
Trained as a scientist with experience in both operational and strategic roles, Ms. Gulfo has been awarded five U.S. patents for innovative packaging designed to help patients adhere to their medicines. She serves as an innovation advisor to PARTNERS Healthcare, the $10 billion Boston-based healthcare system, and Cleveland Clinic’s Innovation Center. She also serves on the board of directors for Volunteers of America (VOA) – Greater New York, and is a member of the Committee of 200 (C200), the world’s premier women’s business leadership organization.
Among many honors, she is especially proud of receiving the 2015 Pinnacle in Leadership Award for STEM from the Girl Scouts of Greater New York, and being honored as one of the top 100 Corporate Leaders in STEM. She holds a bachelor's degree in biology from Seton Hall University and an MBA from Fairleigh Dickinson University. She also studied post-graduate Molecular Biology and began her career at the University of Medicine and Dentistry of New Jersey.
Rodney ZemmelDirector, Managing Partner – Northeast Offices McKinsey & Company
Rodney serves as the managing partner of McKinsey's offices in the Northeast United States (New York, Boston and Stamford). He was previously leader of our Healthcare Systems and Services Practice. He advises clients across the healthcare spectrum, working with leading companies in pharmaceuticals, health insurance and healthcare-benefit management, as well as hospital systems and academic medical centers. He also serves clients across industries on growth strategy.
Rodney has helped develop strategies for clients responding to major market disruptions, such as US healthcare reform, and R&D productivity challenges. He has worked extensively on mergers and acquisitions, partnerships, organizational transformation, and post-merger integrations. He has also supported launch and growth strategies for a number of leading products in the United States, Europe, and Japan, helping deliver important benefits to patients and improved business results for clients. He has led McKinsey's support for a number of private-equity clients investing in healthcare.
Rodney has authored articles in leading healthcare business publications such as Nature, Drug Discovery and In Vivo on the topics of R&D and innovation. He contributes to research efforts by the McKinsey Global Institute and is a frequent speaker at industry conferences.
Managing Director, Houlihan Lokey
Mr. De Rose is a Managing Director in Houlihan Lokey Howard & Zukin's New York office, where his primary responsibilities providing investment banking, valuation and transactional opinion services. He is a member of the Firm's Fairness, Solvency and Technical Standards Committees. With over 20 years of investment banking experience, he has extensive expertise in successfully managing complex transactions across a broad spectrum of industries.
Before joining Houlihan Lokey, Mr. De Rose served as managing director in the Mergers & Acquisitions Group of Bear, Stearns & Co. Inc. In that capacity, he advised clients in negotiated mergers and acquisitions, divestitures, leveraged buyouts, contested takeovers, and proxy fights — completing over 100 M&A transactions. He was also a managing director in the Bear Stearns's Financial Restructuring Group, advising debtors, senior lenders, bondholders and prospective acquirers of Chapter 11 debtors and other financially distressed companies. He also served as a member of Bear Stearns' Valuation Committee.
Mr. De Rose began his career as a corporate attorney at Wachtell, Lipton, Rosen & Katz. His responsibilities there included providing counsel to clients in M&A transactions and public and private securities offerings, as well as advising banks and institutional investors in connection with debt financings and troubled loan workouts.
Mr. De Rose earned a B.A. in philosophy from the University of Pennsylvania, a Ph.D. in philosophy from Brown University and a J.D. from the New York University School of Law. He is a member of the Association of the Bar of the City of New York, the American Bar Association and American Bankruptcy Institute. He is registered with FINRA as a General Securities Representative (Series 7 and 63) and a Limited Representative — Investment Banking (Series 79).